Blood Journal
Leading the way in experimental and clinical research in hematology

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

  1. May S. Kung Sutherland1,
  2. Roland B. Walter2,3,
  3. Scott C. Jeffrey1,
  4. Patrick J. Burke1,
  5. Changpu Yu1,
  6. Heather Kostner1,
  7. Ivan Stone1,
  8. Maureen C. Ryan1,
  9. Django Sussman1,
  10. Robert P. Lyon1,
  11. Weiping Zeng1,
  12. Kimberly H. Harrington2,
  13. Kerry Klussman1,
  14. Lori Westendorf1,
  15. David Meyer1,
  16. Irwin D. Bernstein2,4,
  17. Peter D. Senter1,
  18. Dennis R. Benjamin1,
  19. Jonathan G. Drachman1, and
  20. Julie A. McEarchern1
  1. 1Department of Research & Translational Medicine, Seattle Genetics, Inc., Bothell, WA;
  2. 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and
  3. 3Division of Hematology/Department of Medicine, and
  4. 4Department of Pediatrics, University of Washington, Seattle, WA
  1. Partially presented as a poster at the 54th annual meeting of the American Society of Hematology, Atlanta, GA, December 10, 2012.

You do not have access to the full text of this article, the first page of the PDF of this article appears below.

PDF extract preview

To view this item, select one of the options below

If you already have a subscription, you may gain access using your ASH username and password.

Sign In for Institutional Administrators

If you are a Librarian or institutional account administrator you can use this link to manage your account and view usage reports.

 

Purchase Short-Term Access

Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00.
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

OpenAthens Users

Log in through your institution

Sign Up

Subscribe to the Journal - Subscribe to the print and/or online journal.

Access for Patients

Access for Patients - Patients desiring access should contact the journal.